Promising new combo targets tough childhood liver cancer
NCT ID NCT07188311
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests a combination of three drugs (pucotenlimab, lenvatinib, and irinotecan) in children aged 2-18 with advanced hepatoblastoma that has not responded to prior treatment. The goal is to see if this combo can control the cancer longer. Participants will receive the treatment in 3-week cycles, and researchers will monitor tumor growth and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yizhuo Zhang
RECRUITINGGuangdong, Guangzhou, 510060, China
Conditions
Explore the condition pages connected to this study.